Dec 13 2024 10 mins
Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, participants will be able to: Explain the key characteristics of an oncolytic immunotherapy for advanced melanoma; Discuss the rationale for combining an oncolytic immunotherapy and a systemic immunotherapy in patients with melanoma who have progressed on an anti-PD1 therapeutic regimen; Evaluate the latest clinical data for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma who have progressed on an anti-PD1 therapy; and Use patients and disease characteristics to identify patient eligibility and suitability for oncolytic immunotherapy in combination with a systemic immunotherapy in patients with advanced melanoma.